ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

UAMS Reports Bone Loss From Oral Diabetes Drug

  [ 30 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 9, 2003


LITTLE ROCK, Ark., Oct. 8 /PRNewswire/ -- Scientists at the University of Arkansas for Medical Sciences (UAMS) report in the journal Endocrinology that a widely used oral drug for type 2 diabetes may pose a significant risk of bone loss.

The researchers report that in a laboratory study the anti-diabetic compound rosiglitazone (known as Avandia), caused a significant decrease in total body bone mineral density, suggesting that Avandia therapy may pose a significant risk of adverse skeletal effects in humans.

"Avandia is an FDA-approved and clinically successful treatment for type 2 diabetes. Our findings suggest that doctors should watch the skeletons of patients who use this drug, especially older patients, because their patients may be at increased risk of bone loss over time," said lead researcher Beata Lecka-Czernik, Ph.D., a molecular and cell biologist.

An estimated 16 million Americans have type 2 diabetes, which results from insulin resistance, a condition in which the body does not properly use insulin, along with relative insulin deficiency. The disease typically develops in people over the age of 40. Rosiglitazone, a very effective anti-diabetic agent that reduces insulin resistance, has had federal approval since 1999.

The National Institute on Aging funded the research at UAMS with a five-year, $925,000 grant. Physiologists and endocrinologists Larry J. Suva, Ph.D., and Dana Gaddy, Ph.D., are co-investigators. Lecka-Czernik is a member of the Donald W. Reynolds Department of Geriatrics and Suva and Gaddy are members of the faculty of the Departments of Orthopaedic Surgery and Physiology and Biophysics, all in the UAMS College of Medicine. All three researchers are members of the Arkansas Cancer Research Center at UAMS. S. O. Rzonca and D. C. Montague, research assistants who conducted the experiment and technical analyses, are co-authors of the article in Endocrinology.

The UAMS scientists used micro-computed tomography to analyze the bones of healthy mice that received doses of rosiglitazone over seven weeks. The doses that mice received were the same doses mice received in earlier studies that demonstrated the compound's effectiveness for type 2 diabetes. The researchers next plan to test the effects of the drug on mice and rats with diabetes. Lecka-Czernik also has a grant for the follow-up study of $300,000
for three years from the American Diabetes Association.

A gift of $288,000 from the Roy and Christine Sturgis Charitable Trust in 2002 enabled UAMS to purchase the sophisticated bone analysis equipment used in the study.

The journal Endocrinology is published by The Endocrine Society. UAMS is the leading biomedical research institution in Arkansas and the home of the Donald W. Reynolds Center on Aging as well as the Donald W. Reynolds Department of Geriatrics.

SOURCE: University of Arkansas for Medical Sciences
Web Site: http://www.uams.edu



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg FibroSleep™ Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life
Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map